Kazushi Tanimoto

Comparison of quantitative PCR values and antigenemia for CMV monitoring in hematopoietic cell transplant recipients

Yasuo Mori, Kentaro Kohno, Toshiyuki Ueno, Jun Odawara et autres

jp (code pays fourni par la source)

Impact of Oral Eicosapentaenoic Acid on Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Onset Prevention: Single-Center Retrospective Analysis

Yukihiro Miyazaki, Hiroshi Narumi, Taichi Azuma, Kazushi Tanimoto et autres

jp (code pays fourni par la source)

Development of a New CAR-T-Cell Therapy Targeting an Immune Checkpoint for Effective Treatment of Solid and Liquid Tumors

Toshiki Ochi, Yuko Matsuoka, Tatsuya Konishi, Masaki Maruta et autres

Development of a new CAR-T-cell therapy against relapsed/refractory malignancies including solid tumors is an interest and a struggling issue. Immune-checkpoint blockade therapy is a successful modality for the treatment of solid tumors. We hypothesized that CAR-T-cell therapy targeting immune-checkpoint protein expressed by …

jp (code pays fourni par la source)

Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study

Yasuo Mori, Naoyuki Uchida, Atsushi Wake, Kohta Miyawaki et autres

jp (code pays fourni par la source)

Reinforced antimyeloma therapy via dual-lymphoid activation mediated by a panel of antibodies armed with bridging-BiTE

Tatsuya Konishi, Toshiki Ochi, Masaki Maruta, Kazushi Tanimoto et autres

Immunotherapy using bispecific antibodies including bispecific T-cell engager (BiTE) has the potential to enhance the efficacy of treatment for relapsed/refractory multiple myeloma. However, myeloma may still recur after treatment because of downregulation of a target antigen and/or myeloma cell heterogeneity. To strengthen …

jp (code pays fourni par la source)

Supplementary Figure 1 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai et autres

PDF file - 5868K, A. Tumor growth in mice treated with activated NK cells combined with rituximab was serially measured using in vivo bioluminescence assay. Two mice (NK-No.1* and NK-No.2**) were euthanized at different time points on day 14 and day 18, …

Supplementary Figure 2 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai et autres

PDF file - 4938K, A. Representative patterns of tumor growth displayed in mice treated with cCD16ζ-T cells in combination with rituximab in the late phase determined using in vivo bioluminescence assay. In mice treated with cCD16ζ-T cells combined with rituximab, tumor growth …

Data from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai et autres

Abstract The central tumoricidal activity of anticancer monoclonal antibodies (mAb) is exerted by FcγR IIIa (CD16)–expressing effector cells in vivo via antibody-dependent cell-mediated cytotoxicity (ADCC), as observed for natural killer (NK) cells. In practice, chemotherapy-induced leukopenia and exhaustion of NK cells resulting …

Supplementary Figure 2 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai et autres

PDF file - 4938K, A. Representative patterns of tumor growth displayed in mice treated with cCD16ζ-T cells in combination with rituximab in the late phase determined using in vivo bioluminescence assay. In mice treated with cCD16ζ-T cells combined with rituximab, tumor growth …

Supplementary Figure 1 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai et autres

PDF file - 5868K, A. Tumor growth in mice treated with activated NK cells combined with rituximab was serially measured using in vivo bioluminescence assay. Two mice (NK-No.1* and NK-No.2**) were euthanized at different time points on day 14 and day 18, …

Data from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai et autres

Abstract The central tumoricidal activity of anticancer monoclonal antibodies (mAb) is exerted by FcγR IIIa (CD16)–expressing effector cells in vivo via antibody-dependent cell-mediated cytotoxicity (ADCC), as observed for natural killer (NK) cells. In practice, chemotherapy-induced leukopenia and exhaustion of NK cells resulting …

Supplementary Figure S2 from Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia

Hiroki Tanaka, Hiroshi Fujiwara, Fumihiro Ochi, Kazushi Tanimoto et autres

ADCC activity mediated by cCD16ζ-T cells against Mog-opsonized ATL tumor cells was dependent on both effector cell number and Mog dose. However, at a pharmacological dose of Mog, the decline of ADCC was more obviously dependent on the number of effector cells. …